RDS raises €14 million to industrialize MultiSense®, a connected patch for remote patient monitoring

(MENAFN- ALA Group) Funds raised will help accelerate time to market in Europe for MultiSense and scale industrial operations

Plans include starting a health economics study to support MultiSense’s reimbursement application, alongside preparing registration procedures with US authorities, with an eye on US launch in 2028

Strasbourg, France, September 29, 2025 – RDS, a French medtech company, today announces a €14 million ($16.6M) Series A funding round. The SPI (Sociétés de Projets Industriels) fund, managed on behalf of the French state by Bpifrance, led the round, with Critical Path Ventures also taking a new stake. MACSF, Capital Grand Est and other historical investors also contributed.

Investors are backing RDS’ MultiSense®, a CE-marked, class IIa remote monitoring medical device, which provides healthcare professionals with a high-precision, comprehensive solution for continuous monitoring of patients’ key physiological parameters in hospital or at home. This innovative, clinically validated technology has already been rolled out in 15 hospitals across France, Belgium and Germany. In the last year, the device was added to the approved supplies list for RESAH and UniHA, leading public purchasing bodies for hospitals in France.

RDS will use the funds to accelerate its development in France, Germany and the broader European market. The company expects to create several hundred new jobs by 2035, bolstering its sales team to meet the growing demand for the MultiSense solution. The funds will also finance the industrialization of the solution that is manufactured in France, with the aim of gradually ramping up production and refurbishing capacities.

Simultaneously, RDS will launch complementary clinical trials to support its applications for reimbursement in France and across Europe. The company is also preparing to initiate the FDA registration process, with a view to a US market launch in 2028.

“This investment gives us the means to ramp up our sales growth in Europe, consolidate the clinical and health economic value of MultiSense, and get ready for market launch in North America,” said Elie Lobel, CEO of RDS.“These funds mean we can roll out our solution more widely to hospitals, expand its positive impact for patients and care teams, and provide reliable, continuous, clinically validated remote monitoring to as many facilities as possible. The funds raised are a testament to our investors’ enduring confidence in this project and the team.”

With this financing, RDS will have raised a total of €28 million since its founding. The Series A €14 million comes on top of the €14 million in capital and non-dilutive financing provided by the French government, notably through the France 2030 investment plan, facilitated by Bpifrance, as well as by the Grand-Est regional authority and the European Union, within the scope of several research projects.

"France 2030 is proud to have supported this project since 2020 and to work today with SPI on the rapid industrialization and effective deployment of the solution for the benefit of patients. RDS’ story clearly shows how France 2030 is capable of transitioning a project from the lab stage to becoming an international champion," said Bruno Bonnell, Secretary General for Investment, in charge of France 2030.

In parallel with this funding round, Laurent Monnin, senior investment director at Bpifrance, joins the company’s strategic board, as does Nicolas Foessel, representing Critical Path Ventures.

“We are delighted to be supporting RDS in this critical phase of its development,” said Magali Joëssel, director of the SPI fund at Bpifrance. “This funding gives the company the means to become a leading player in post-operative remote monitoring through MultiSense, and a pioneer in the medicine of the future. By scaling the manufacturing of its solution, RDS fully embodies the principle of the SPI fund: funding the industrialization of innovative technologies that will bring growth and jobs to France.”

“We believe that the key to transforming the healthcare system is useful innovation and industrial ambition,” said Nicolas Foessel of Critical Path Ventures. “With our investment in RDS, we are backing a team that combines technological excellence with clinical impact and a long-term vision for medicine, with emphasis on a more preventive, smoother and human approach. MultiSense exemplifies this positioning, enabling continuous monitoring and meeting patients’ particular needs away from the hospital setting.”

“The funding provided by SPI and Critical Path Ventures is a real asset for RDS, which will be able to ramp-up activities after a launch phase to which MACSF and Capital Grand Est have contributed,” said Jean-François Rax, partner at Capital Grand Est.

The global market for vital signs monitoring is estimated at USD $15 billion in 2025, and is expected to grow by an average of 15% each year until 2030. This progression reflects a strong shift towards home-based patient care both in France and internationally, driven by the desire to relieve pressure on hospitals, reduce duration of stay and improve post-operative monitoring. The Covid-19 pandemic also brought about a significant shift in outlook, accelerating the adoption of remote monitoring and strengthening the requirement for reliable, interoperable digital solutions.

"ERAS (Enhanced Recovery After Surgery) studies have shown the importance of short hospital stays, even after a major surgery. However, the use of these protocols remains limited because surgeons have to engage their responsibility. The MultiSense patch offers an ideal solution: faster patient discharge and a more effective monitoring of vital signs than in hospital, with considerable medical and economic benefits expected. This is a major challenge for the sustainability of our healthcare system," concluded Jacques Marescaux, professor of surgery, president and founder of IRCAD, and member of RDS’ Scientific Board.

About MultiSense
The MultiSense solution combines a wearable patch with a cloud-based platform and associated support services. It continuously monitors six key parameters, including heart rate, respiratory rate and oxygen saturation. The solution is protected by more than 20 patents. From the outset, sustainability has been a core focus: the device can be cleaned, refurbished and reused to minimize its carbon footprint. MultiSense is designed to support the implementation of short-stay hospitalization protocols, helping to reduce the average length of hospital stays, to ensure safer hospital discharge and to improve patients’ quality of life.

About Bpifrance and the SPI (Société de Projets Industriels) fund
Bpifrance finances companies – at each stage of their development – in credit, guarantees and equity. It supports them in their innovation and international projects. Bpifrance also ensures their export activity through a wide range of products. Consulting, university, networking and acceleration programs for startups, SMEs and midcaps are also part of the offer available to entrepreneurs. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, unique and efficient contact person to help them face their challenges.
The SPI fund, managed by Bpifrance on behalf of the French state in connection with the France 2030 plan, is intended to help industrial projects with the best business and employment opportunities for industrial sectors to find support for their development. The fund acts as an informed investor taking stakes in project companies with industrialization projects, which are selected for their growth potential, the current positioning of the industry and their contribution to the environmental and energy transition. As such, it is one of the financial levers of the New Industrial France (Nouvelle France Industrielle) policy.
- presse.bpifrance.fr/ -
Follow us on X: @Bpifrance - @BpifrancePresse and LinkedIn

About Critical Path Ventures
Since 2022, Critical Path Ventures has been investing in innovative scientific research projects, providing financial support to startups created by researcher-entrepreneurs from the seed stage onwards.
Critical Path Ventures selects an average of six projects per year, often on a co-investment basis and mainly in the fields of physics, medicine, biotechnology, and robotics, promoting industrial development and job retention in France.


About MACSF Group
France’s leading insurer for health care professionals, MACSF (Mutuelle d’assurance du corps de santé français) has over 100 years’ experience in providing services to all those employed in health care occupations. It employs 1,700 people and generates revenues of more than €3 billion ($3.5bn). In keeping with its mission as a professional mutual insurer, MACSF provides cover for personal and occupational risks for over one million members and customers.


About Capital Grand Est
Capital Grand Est is an independent regional investment capital company accredited by the French Financial Markets Authority (AMF). Since 2012, its 14-strong team has provided support to more than 70 companies in France’s Grand Est and Bourgogne-Franche-Comté regions. With more than €220 million ($259.5M) in assets under management across six investment vehicles, Capital Grand Est organizes various capital transactions for different types of business in the region to accelerate their paths to success. It offers capital-intensive seed round support for innovative young start-ups. For more established companies, it structures development capital transactions to expedite their growth and buyouts to support them in their capital developments. Finally, for companies in transition, it organizes a capital rebound operation to consolidate the steps taken and promote the rebound of their business.


About the France 2030 investment plan
It has a dual ambition: to sustainably transform key sectors of the French economy (health, energy, automotive, aeronautics and space industries) through technological innovation, and to position France not just as a participant, but as a leader in shaping the world of tomorrow. From fundamental research to the emergence of an idea and the production of a new product or service, France 2030 supports the entire innovation lifecycle up to its industrialization
It is unprecedented in scale: €54 billion will be invested to ensure that French businesses, universities and research organizations successfully navigate transitions in these strategic industries. The goal: to enable them to respond competitively to the ecological and attractiveness challenges of the future and to foster the emergence of future leaders in French fields of excellence. France 2030 is defined by two overarching objectives: dedicating 50% of its expenditures to decarbonizing the economy and 50% to emerging actors driving innovation, without any spending detrimental to the environment (in line with the ‘Do No Significant Harm’ principle)
It is implemented collectively: designed and deployed in consultation with economic, academic, local and European stakeholders to define strategic directions and flagship actions. Project leaders are invited to submit their proposals through open, rigorous and selective procedures to benefit from state support
It is overseen by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Agency for Ecological Transition (ADEME), the National Research Agency (ANR), Bpifrance and the Banque des Territoires.
For more information, visit: | @SGPI_avenir

MultiSense® is a class IIa medical device manufactured and marketed by RDS SAS. It is a regulated healthcare product and carries a CE mark in accordance with Regulation (EU) 2017/745 (notified body: Eurofins Product Testing Italy S.r.l., no. 0477). It does not benefit from reimbursement at this time. Further information about the device can be found in the instructions for use.

MENAFN29092025005466016124ID1110123669